Gain Therapeutics Inc
GANX1.470USD
+0.030+2.08%
收盘 08/04, 16:00（美东）报价延迟15分钟
1.470USD+1.470盘后交易 (美东)
42.26M总市值
亏损市盈率 TTM
单季报
单季报+年报
单季报
年报
YOY
隐藏空白行
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q2
FY2020Q1
营业总收入
----
--0.00
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
-100.00%0.00
22.61%55.18K
-100.00%0.00
-100.00%0.00
6.65%95.10K
754.17%45.01K
--43.21K
--27.34K
1299.23%89.17K
-21.04%5.27K
--6.37K
--6.67K
营业收入
----
----
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
-100.00%0.00
22.61%55.18K
-100.00%0.00
-100.00%0.00
6.65%95.10K
754.17%45.01K
--43.21K
--27.34K
1299.23%89.17K
-21.04%5.27K
--6.37K
--6.67K
营业费用
-0.19%4.37M
-24.42%3.33M
-8.72%4.46M
5.84%8.18M
-17.17%4.38M
-3.38%4.41M
2.82%4.89M
46.66%7.73M
58.54%5.28M
40.26%4.56M
1.88%4.75M
46.28%5.27M
34.84%3.33M
--3.25M
--4.66M
568.80%3.60M
376.40%2.47M
--538.84K
--518.93K
研发费用
-10.04%2.22M
-49.86%1.19M
9.24%2.59M
10.40%4.40M
-11.47%2.47M
4.40%2.37M
20.50%2.37M
54.44%3.99M
79.33%2.79M
54.42%2.27M
-20.67%1.96M
43.98%2.58M
9.49%1.56M
--1.47M
--2.48M
308.67%1.79M
240.68%1.42M
--438.87K
--417.26K
折旧摊销及损耗
0.64%20.66K
-6.74%22.00K
7.27%22.00K
3.76%21.00K
6.68%20.53K
30.25%23.59K
15.04%20.51K
1.09%20.24K
134.40%19.24K
212.89%18.11K
330.84%17.83K
827.76%20.02K
141.23%8.21K
--5.79K
--4.14K
-5.18%2.16K
61.97%3.40K
--2.28K
--2.10K
营业利润
0.19%-4.37M
24.42%-3.33M
8.72%-4.46M
-5.84%-8.18M
16.29%-4.38M
3.38%-4.41M
-2.82%-4.89M
-49.35%-7.73M
-59.03%-5.23M
-42.15%-4.56M
-2.48%-4.75M
-47.28%-5.18M
-33.30%-3.29M
---3.21M
---4.64M
-560.06%-3.51M
-381.57%-2.47M
---532.47K
---512.26K
净非营业利息收入（费用）
出售证券收益
-137.52%-100.59K
103.86%15.76K
-247.37%-121.14K
27.61%-43.58K
725.73%268.08K
-105.34%-408.51K
89.00%82.20K
-249.69%-60.20K
-323.58%-42.84K
-911.13%-198.94K
258.66%43.49K
190.63%40.21K
3.36%19.16K
---19.68K
---27.41K
-813.55%-44.37K
126.90%18.54K
---4.86K
---68.91K
税前利润
-10.90%-4.43M
30.70%-3.26M
4.73%-4.47M
-6.27%-8.14M
21.99%-3.99M
-2.46%-4.71M
-3.13%-4.70M
-50.93%-7.66M
-56.55%-5.12M
-42.38%-4.60M
2.24%-4.55M
-42.87%-5.08M
-33.67%-3.27M
---3.23M
---4.66M
-559.39%-3.55M
-319.78%-2.45M
---538.84K
---582.92K
所得税
405.73%100.51K
3380.47%504.74K
-48.76%10.99K
-95.45%1.21K
18.81%19.87K
-81.43%14.50K
430.04%21.46K
190.72%26.59K
897.50%16.73K
1047.42%78.11K
-20.84%4.05K
149.89%9.15K
-51.80%1.68K
---8.24K
--5.11K
-19.08%3.66K
158.28%3.48K
--4.52K
--1.35K
除税后利润
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
持续经营利润
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
归属于母公司的净利润
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
归属于普通股东的净利润
-12.85%-4.53M
20.23%-3.77M
4.93%-4.49M
-5.92%-8.14M
21.86%-4.01M
-1.06%-4.72M
-3.51%-4.72M
-51.18%-7.69M
-56.98%-5.14M
-45.17%-4.67M
2.26%-4.56M
-42.98%-5.09M
-33.55%-3.27M
---3.22M
---4.66M
-554.57%-3.56M
-319.40%-2.45M
---543.36K
---584.27K
基本每股收益
29.27%-0.16
56.76%-0.14
54.49%-0.17
31.72%-0.42
48.13%-0.22
20.04%-0.31
3.15%-0.37
-45.03%-0.62
-56.30%-0.43
-45.38%-0.39
2.31%-0.38
-42.90%-0.43
-33.48%-0.28
---0.27
---0.39
-524.55%-0.30
-300.17%-0.21
---0.05
---0.05
稀释每股收益
29.27%-0.16
56.76%-0.14
54.49%-0.17
31.72%-0.42
48.13%-0.22
20.04%-0.31
3.15%-0.37
-45.03%-0.62
-56.30%-0.43
-45.38%-0.39
2.31%-0.38
-42.90%-0.43
-33.48%-0.28
---0.27
---0.39
-524.55%-0.30
-300.17%-0.21
---0.05
---0.05
每股派息
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
货币单位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
审计意见
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
